Evidence map›Paper›PMID 40427602›Full record

ReviewBiomolecules2025

Role of Tumor Necrosis Factor in Tuberculosis.

Fedor D Kireev, Julia A Lopatnikova, Alina A Alshevskaya, Sergey V Sennikov

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. HowVaccines · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Silymarin Reduces the Inflammatory Response and the Burden ofInternational journal of microbiology · 2026
    Article
  8. Article
  9. Physiological stage-dependent effects ofFrontiers in microbiology · 2025
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fedor D KireevLaboratory of Molecular Immunology, Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology" (RIFCI), 630099 Novosibirsk, Russia.ORCID 0009-0008-9309-6676
Julia A LopatnikovaLaboratory of Molecular Immunology, Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology" (RIFCI), 630099 Novosibirsk, Russia.ORCID 0000-0003-0089-5054
Alina A AlshevskayaLaboratory of Immune Engineering, Federal State Autonomous Educational Institution of Higher Education "I.M. Sechenov First Moscow State Medical University" under the Ministry of Health of the Russian Federation (Sechenov University), 119048 Moscow, Russia.ORCID 0000-0002-7307-4524
Sergey V SennikovLaboratory of Molecular Immunology, Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology" (RIFCI), 630099 Novosibirsk, Russia.ORCID 0000-0002-7366-7768

Funding

Russian Science Foundation №20-75-10051
6 · The paper itself

Abstract

Tumor necrosis factor (TNF) is a key immunoregulatory cytokine with a dual role in the host response to

Indexed as

TuberculosisTumor Necrosis Factor-alphaAnimalsGranulomaHumansMycobacterium tuberculosisSignal TransductionTumor Necrosis Factor-alphaAnti-TNF therapyTNFTNFR1TNFR2Tuberculosis

Identifiers

PMID40427602
PMCPMC12108764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.